Andere Sprachen ACADIA Pharmaceuticals Inc.

Aktien

603035

US0042251084

ACAD

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 03.12.2024			% 5 Tage	% 1. Jan.
16.30 ^USD	-1.87%		+0.56%	-47.94%

03.12.	ACADIA Pharmaceuticals Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 10:15 AM
28.11.	Saniona steigert Umsatz - aber auch Betriebsverlust	FW

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Saniona's CEO to BioStock: "The deal with Acadia is significant"	28.11.
Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront	26.11.
Saniona Announces Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases	26.11.
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711	26.11.
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences	21.11.
Acadia Pharmaceuticals Terminates COO Brendan Teehan	20.11.
ACADIA Pharmaceuticals Inc. Announces Executive Changes	20.11.
Acadia Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	18.11.
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	15.11.
Neuren Pharmaceuticals to Launch AU$50 Million Share Buyback; Shares Up 6%	14.11.
ACADIA Pharmaceuticals : Corporate Presentation	11.11.
Neuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%	07.11.
Acadia Pharmaceuticals : Reports Third Quarter 2024 Financial Results and Operating Overview Form 8 K	06.11.
Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q3 Revenue $250.4M	06.11.
Acadia: Q3 Earnings Snapshot	06.11.
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview	06.11.
ACADIA Pharmaceuticals Inc. Revises Earnings Guidance for the Year 2024	06.11.
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	06.11.
Neuren Pharmaceuticals' US Partner to Sell Rare Pediatric Disease Priority Review Voucher for $150 Million; Shares Up 6%	06.11.
Acadia Pharmaceuticals to Sell Priority Review Voucher for $150 Million	05.11.
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million	05.11.
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024	18.10.
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE for the Treatment of Rett Syndrome	17.10.
Neuren Pharmaceuticals' Rett Syndrome Drug Secures Approval in Canada	17.10.
ACADIA Pharmaceuticals' Rett Syndrome Treatment Gets Health Canada Approval	16.10.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ACADIA Pharmaceuticals Inc.

Aktien

603035

US0042251084

ACAD

Biotechnologie

Andere Sprachen

Filter